Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

M. van Gelder; M. H. van Oers; W. G. Alemayehu; M. C. J. Abrahamse-Testroote; J. J. Cornelissen; M. E. Chamuleau; P. Zachee; M. Hoogendoorn; M. Nijland; E. J. Petersen; A. Beeker; G-J Timmers; L. Verdonck; M. Westerman; O. de Weerdt; A. P. Kater

doi:10.1038/bmt.2016.9

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

M. van Gelder^*, M. H. van Oers, W. G. Alemayehu, M. C. J. Abrahamse-Testroote, J. J. Cornelissen, M. E. Chamuleau, P. Zachee, M. Hoogendoorn, M. Nijland, E. J. Petersen, A. Beeker, G-J Timmers, L. Verdonck, M. Westerman, O. de Weerdt, A. P. Kater

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Web of Science)

Abstract

Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) = 3 cycles of R-DHAP and sixteen

Original language	English
Pages (from-to)	799-806
Journal	Bone Marrow Transplantation
Volume	51
Issue number	6
DOIs	https://doi.org/10.1038/bmt.2016.9
Publication status	Published - Jun 2016

Access to Document

10.1038/bmt.2016.9

Cite this

van Gelder, M., van Oers, M. H., Alemayehu, W. G., Abrahamse-Testroote, M. C. J., Cornelissen, J. J., Chamuleau, M. E., Zachee, P., Hoogendoorn, M., Nijland, M., Petersen, E. J., Beeker, A., Timmers, G-J., Verdonck, L., Westerman, M., de Weerdt, O., & Kater, A. P. (2016). Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. Bone Marrow Transplantation, 51(6), 799-806. https://doi.org/10.1038/bmt.2016.9

@article{ec477134f94149b4afe645a0a7705940,

title = "Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study",

abstract = "Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) = 3 cycles of R-DHAP and sixteen ",

author = "{van Gelder}, M. and {van Oers}, {M. H.} and Alemayehu, {W. G.} and Abrahamse-Testroote, {M. C. J.} and Cornelissen, {J. J.} and Chamuleau, {M. E.} and P. Zachee and M. Hoogendoorn and M. Nijland and Petersen, {E. J.} and A. Beeker and G-J Timmers and L. Verdonck and M. Westerman and {de Weerdt}, O. and Kater, {A. P.}",

year = "2016",

month = jun,

doi = "10.1038/bmt.2016.9",

language = "English",

volume = "51",

pages = "799--806",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "6",

}

van Gelder, M, van Oers, MH, Alemayehu, WG, Abrahamse-Testroote, MCJ, Cornelissen, JJ, Chamuleau, ME, Zachee, P, Hoogendoorn, M, Nijland, M, Petersen, EJ, Beeker, A, Timmers, G-J, Verdonck, L, Westerman, M, de Weerdt, O & Kater, AP 2016, 'Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study', Bone Marrow Transplantation, vol. 51, no. 6, pp. 799-806. https://doi.org/10.1038/bmt.2016.9

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. / van Gelder, M.; van Oers, M. H.; Alemayehu, W. G. et al.

In: Bone Marrow Transplantation, Vol. 51, No. 6, 06.2016, p. 799-806.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

AU - van Gelder, M.

AU - van Oers, M. H.

AU - Alemayehu, W. G.

AU - Abrahamse-Testroote, M. C. J.

AU - Cornelissen, J. J.

AU - Chamuleau, M. E.

AU - Zachee, P.

AU - Hoogendoorn, M.

AU - Nijland, M.

AU - Petersen, E. J.

AU - Beeker, A.

AU - Timmers, G-J

AU - Verdonck, L.

AU - Westerman, M.

AU - de Weerdt, O.

AU - Kater, A. P.

PY - 2016/6

Y1 - 2016/6

N2 - Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) = 3 cycles of R-DHAP and sixteen

AB - Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) = 3 cycles of R-DHAP and sixteen

U2 - 10.1038/bmt.2016.9

DO - 10.1038/bmt.2016.9

M3 - Article

SN - 0268-3369

VL - 51

SP - 799

EP - 806

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 6

ER -